ReviewPharmaceutical research2006
Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.
Review in Pharmaceutical research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Identifying widespread and recurrent variants of genetic parts to improve annotation of engineered DNA sequences.PloS one · 2024Article
- How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?International journal of molecular sciences · 2021Review
- Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Current status of non-viral gene therapy for CNS disorders.Expert opinion on drug delivery · 2016Review
- Feline neural progenitor cells II: use of novel plasmid vector and hybrid promoter to drive expression of glial cell line-derived neurotrophic factor transgene.Stem cells international · 2012Article
- Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design.Gene therapy · 2011Article
- Targeted gene-silencing reveals the functional significance of myocardin signaling in the failing heart.PloS one · 2011Article
- The impact of intragenic CpG content on gene expression.Nucleic acids research · 2010Article
- Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.The Journal of clinical investigation · 2009Article
- Nonviral approaches for neuronal delivery of nucleic acids.Pharmaceutical research · 2008Review
- Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy requires the introduction of genetic material in diseased cells with the aim of treating or ultimately curing a disease. Since the start of gene therapy clinical trials in 1990, gene therapy has proven to be possible, but studies to date have highlighted the difficulty of achieving efficient, specific, and long-term transgene expression. Efforts to improve gene therapy strategies over the past years were mainly aimed at solving the problem of delivery, without paying much attention to the optimization of the expression cassette. With the current understanding of the eukaryotic transcription machinery and advanced molecular biology techniques at our disposition, it has now become possible to create custom-made transgene expression cassettes optimized for gene therapy applications. In this review, we will discuss several strategies that have been explored to improve the level and duration of transgene expression, to increase control over expression, or to restrict transgene expression to specific cell types or tissues. Although still in its infancy, such strategies will eventually lead to improvement of nonviral gene therapy and expansion of the range of possible therapeutic applications.
Indexed as
Identifiers
16715361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.